Description: Enochian Biosciences Inc., a pre-clinical stage biotechnology company, focuses on development of human therapeutics for infectious diseases and cancers. The company's lead candidate include ENOB-HV-01 for autologous HIV curative treatment. Its pipeline development products consist of ENOB-HV-11, a preventive HIV vaccine; and ENOB-HV-12, a therapeutic HIV vaccine. The company's pipeline development products also include ENOB-DB-01, a therapeutic cancer vaccine for the long term maintenance and prevention of relapse for the treatment of stage III and IV colon cancer patients; ENOB-DC-11 Innovative DC vaccine for multiple solid tumors; and ENOB-DC-21 for intratumoral injection. The company has strategic partnerships with The Scripps Institute and Fred Hutchinson Cancer Center. Enochian BioSciences was incorporated in 2017 and is based in Los Angeles, California.
Home Page: www.enochianbio.com
ENOB Technical Analysis
Century City Medical Plaza
Los Angeles,
CA
90067-2012
United States
Phone:
305 918 1980
Officers
| Name | Title |
|---|---|
| Dr. Mark R. Dybul M.D. | CEO, Director & Member of HBV Scientific Advisory Board |
| Ms. Luisa Puche | CFO & Corp. Sec. |
| Ms. Evelyn D'An | Consultant |
| Dr. Serhat Gümrükcü | Co-Founder & Inventor |
| Mr. Greg Duczynski Ph.D. | Sr. VP for Clinical Operations |
| Dr. François Binette M.Sc., Ph.D. | Exec. VP for R&D |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.4499 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2015-02-02 |
| Fiscal Year End: | June |
| Full Time Employees: | 11 |